Stay updated on Pembrolizumab for EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab for EGFR+ NSCLC Clinical Trial page
- CheckyesterdayChange DetectedA new site revision tag v3.5.4 was added, replacing the previous v3.5.3. This reflects an update to the site's build rather than changes to the study details displayed.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page now displays revision v3.5.3, replacing the previous v3.5.2, indicating a maintenance/update to the website's version.SummaryDifference0.1%

- Check30 days agoChange DetectedRevision: v3.5.2 was added and v3.5.0 removed, indicating a minor backend update to the site.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page now shows a new site revision tag 'Revision: v3.5.0' instead of 'Revision: v3.4.3'. This is a minor version update with no impact on the study information.SummaryDifference0.1%

- Check66 days agoChange DetectedRevision: v3.4.3 was added and the previous revision v3.4.2 was removed.SummaryDifference0.1%

- Check95 days agoChange DetectedRevision: v3.4.2 was added; the page removed the government funding lapse notice and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab for EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.